BioCentury
ARTICLE | Company News

Takeda licenses Enterome's Crohn's disease therapy

October 26, 2018 5:07 PM UTC

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) partnered with Enterome Bioscience S.A. (Paris, France) to co-develop the biotech's EB8018 to treat Crohn's disease. The companies will share global development costs as well as U.S. commercialization costs and profits. They will co-promote the product in the U.S., while Takeda will have exclusive commercialization rights outside the U.S.

Enterome will receive $50 million up front and is eligible for $640 million in clinical development, regulatory and commercial milestones, plus tiered, double-digit royalties on ex-U.S. sales. Enterome CEO Pierre Belichard told BioCentury the company will receive a $15 million equity investment from Takeda, but declined to provide details...